期刊文献+

紫杉醇治疗60例妇科恶性肿瘤的临床疗效 被引量:3

The clinical efficacy of 60 cases of gynecological malignancies treated with paclitaxel
下载PDF
导出
摘要 目的探究与分析紫杉醇治疗妇科恶性肿瘤的临床疗效。方法选取我院2012年5月~2014年5月收治的60例妇科恶性肿瘤患者,采取随机数字表法分为A组、B组及C组,A组仅给予紫杉醇治疗,B组给予紫杉醇联合卡铂治疗,C组给予紫杉醇联合异环磷酰胺治疗。观察三组患者的临床疗效。结果 A组患者总有效率为40.00%;B组患者总有效率为60.00%;C组患者总有效率为50.00%,C组患者的总有效率明显高于A组(χ2=4.34,P〈0.05),B组患者的总有效率明显高于C组(χ2=4.25,P〈0.05)。结论采用紫杉醇治疗妇科恶性肿瘤的疗效显著,联合卡铂的疗效更为突出,能够提升患者的生存质量,且为一种理想的治疗方案。 Objective To explore the clinical effiency of gynecologic malignancies and analyse paclitaxel. Methods A total of 60 cases of patients were treated with gynecologic malignancies In our hospital from May 2012 to May 2014 , randomly divided into group A, group B and group C,those in A group only given paclitaxel therapy,and those in group B received paclitaxel plus carboplatin,while those in group C plused paclitaxel and ifosfamide treatment, observing the clinical effiency of three groups of patients. Results A group total effective rate was 40.00%; Group B patients with to- tal effective rate was 60.00%; group C patients with total effective rate was 50.00%. Concluded by the statistic, the ef- fective rate in group C was significantly higher than that in group A. The total effective rate in group B was significant- ly higher than that in group C patients (P〈0.05). Conclusion Taxol treatment of gynecological malignancies lave signifi- cant effect. Combining with cisplatin for better efficacy prominent can improve the quality of life of patients, which can be an ideal treatment plan.
作者 张辉
出处 《中国现代医生》 2014年第31期43-45,共3页 China Modern Doctor
关键词 紫杉醇 卡铂 异环磷酰胺 妇科恶性肿瘤 疗效 Taxol Cisplatin Ifosfamide Gynecological malignancies Efficacy
  • 相关文献

参考文献11

二级参考文献32

  • 1江泽飞.紫杉醇在乳癌治疗中的应用[J].国外医学(肿瘤学分册),1995,22(2):99-101. 被引量:20
  • 2路敏,苏翠金,卢爱霞.癌症患者应用紫杉醇的护理体会[J].齐鲁护理杂志,2005,11(3):242-243. 被引量:19
  • 3周多奇,龚莉.糖尿病运动疗法及其机理[J].安庆师范学院学报(自然科学版),2006,12(3):107-109. 被引量:30
  • 4王哲海,孔莉,于金明.化疗不良反应与对策[M].济南:山东科学技术出版社,2002:29.
  • 5Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial [ J ].Lancet, 2009,374:1331-1338.
  • 6Markman M, Blessing J, Rubin SC, et al. Phase Ⅱ trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study [ J ] Gynecol Oncol, 2006,101:436-440.
  • 7Pignata S, Breda E, Scambia G, et al. A phase Ⅱ study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study [ J ] . Crit Rev Oncol Hematol, 2008,66:229-236.
  • 8Armstrong DK, Bundy B, Wenzel L, et al. lntraperitoneal cisplatin and paclitaxel in ovarian cancer [ J ] . N Engl J Med, 2006,354:34-43.
  • 9Bell J, Brady MF, Young RC, et al. Randomized phase Ⅲ trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study [ J ] . Gyneeol Oncol, 2006, 102:432-439.
  • 10Monk BJ, Sill MW, McMeekin DS, et al. Phase Ⅲ trial of four cisplalin- containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study [ J ] . J Clin Oncol, 2009, 27:4649-4655.

共引文献46

同被引文献20

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部